Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014

Ly, Kathleen N.; Jiles, Ruth; Teshale, Eyasu H.; Foster, Monique A.; Pesano, Rick L.; Holmberg, Scott D.

doi:10.7326/m16-2350

Cited by 129 publications

(122 citation statements)

References 12 publications

Supporting

Mentioning

117

Contrasting

Order By: Relevance

“…This approach may miss a significant fraction of HCV‐infected pregnant women. Moreover, the prevalence of HCV appears to be increasing among women of reproductive age in the US due to increased injection drug use . Thus, an increasing number of infants may be at risk for vertically acquired HCV and potential adverse fetal outcomes including fetal growth restriction and low birth weight.…”

Section: Introductionsupporting

confidence: 91%

Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems

Gowda

Kennedy

Glover

et al. 2018

Paediatric Perinatal Epid

View full text Add to dashboard Cite

Maternal HCV infection is under-recognized and increasing in prevalence. Current case identification processes are inadequate in pregnancy, even among women with prior positive HCV testing. Alternative approaches, including enhanced risk factor-based screening or universal prenatal screening in high prevalence settings, are needed to improve rates of HCV recognition among reproductive-aged women and newborns at risk of vertical transmission.

show abstract

Section: Introductionsupporting

confidence: 91%

Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems

Gowda

Kennedy

Glover

et al. 2018

Paediatric Perinatal Epid

View full text Add to dashboard Cite

show abstract

“…Since these recommendations were established in 2012, HCV epidemiology in the United States has changed. Hepatitis C infection incidence nearly quadrupled from 2010 to 2017, primarily driven by increased injection drug use related to the opioid epidemic . CDC viral hepatitis surveillance data indicate progressively increasing acute HCV infection incidence each year from 2009 through 2017.…”

Section: Universal and Risk‐based Hepatitis C Screening And Follow‐upmentioning

confidence: 99%

“…Additionally, curative DAA therapy during childhood or adolescence supports the HCV treatment as transmission prevention paradigm, a pillar of the 2017 NASEM hepatitis C elimination strategy . The extension of pediatric HCV antiviral treatment to 3‐ through 11‐year‐olds comes at a critical inflexion point in the hepatitis C epidemic, given the recent increase in HCV infection among women of childbearing age and the fact that an estimated 29,000 women with HCV infection gave birth each year from 2011 to 2014 …”

Section: Hcv In the Pediatric Populationmentioning

confidence: 99%

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

2020

View full text Add to dashboard Cite

“…High rates exceeding 6% have been reported in certain hyperendemic regions of countries such as Egypt . In the past decade, the incidence of acute hepatitis C has increased in young adults in the United States, including women of child‐bearing potential, corresponding with a worsening injection opioid epidemic particularly in rural areas and the Appalachian region …”

mentioning

confidence: 99%

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

et al. 2019

View full text Add to dashboard Cite

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to <6 years. In an open‐label study, patients 3 to <6 years old chronically infected with HCV genotype 1 (n = 33) or 4 (n = 1) received weight‐based doses of combined ledipasvir‐sofosbuvir as granules (33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12). For the first 14 patients, intensive pharmacokinetic sampling was done on day 10 of treatment. All patients had been infected through perinatal transmission and were treatment naïve. No patients had known cirrhosis. Ten patients (29%) weighed <17 kg. SVR12 was achieved in 97% of patients (33 of 34); the patient who did not achieve SVR12 was 3 years old and discontinued treatment after 5 days because of an adverse event “abnormal drug taste.” The most common adverse events were vomiting (24% of patients), cough (21%), and pyrexia (21%). No patients experienced a serious adverse event. Intensive pharmacokinetic analysis of 13 patients for whom data were evaluable confirmed that the doses selected were appropriate. Conclusion: Ledipasvir‐sofosbuvir was well tolerated and highly effective in children 3 to <6 years old with chronic HCV infection.

show abstract

Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014

Abstract: Centers for Disease Control and Prevention.

Cited by 129 publications

References 12 publications

Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems

Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Contact Info

Product

Resources

About